Cagrilintide + Retatrutide Stack Protocol - Amylin + Triple Agonist

Cagrilintide + Retatrutide Stack Quick Reference Dosing Card

What Is the Cagrilintide + Retatrutide Stack?

The cagrilintide + retatrutide stack is a community-derived 4-receptor weight-management protocol that pairs two investigational peptides to target weight loss from multiple angles at once. Cagrilintide is a long-acting amylin analogue — it mimics a hormone your body naturally releases after meals to signal fullness. Retatrutide is a triple-agonist peptide that activates three different receptors (GLP-1, GIP, and glucagon) involved in appetite, metabolism, and fat burning. No other current peptide stack covers this breadth of metabolic pathway activation.

The idea behind this stack comes from Novo Nordisk's CagriSema program, which combined cagrilintide with semaglutide (a single-receptor GLP-1 drug). In that trial (REDEFINE 1), adding amylin signaling on top of GLP-1 signaling boosted average weight loss from 14.9% to 20.4%. This stack takes that concept further — it swaps semaglutide for retatrutide, which already hits three receptors instead of one, aiming to layer amylin-driven fullness on top of retatrutide's broader metabolic effects.

No direct clinical trial has evaluated cagrilintide + retatrutide together. Protocols are extrapolated from individual component evidence, including REDEFINE data for cagrilintide and TRIUMPH data for retatrutide. This is one of the most speculative cagrilintide-combination protocols on the site, and the combined gastrointestinal burden — nausea, vomiting, and digestive slowdown from two potent compounds — is a major practical concern.

Why Add Cagrilintide to Retatrutide?

Understanding why someone would add a second compound to an already powerful peptide comes down to one question: does the combination target something the solo compound misses? Here's what each piece brings.

Triple Agonist Foundation — What Retatrutide Already Provides

Retatrutide alone is the most potent single-agent weight-loss peptide in clinical development, with reported mean weight loss up to 28.7% at 68 weeks in TRIUMPH-4. It works through three receptor pathways at once: GLP-1 activation reduces appetite and slows digestion, GIP activation supports metabolic efficiency and insulin sensitivity, and glucagon activation drives energy expenditure and fat burning. See the full retatrutide protocol page for monotherapy context.

The Missing Pathway — Brainstem Amylin Satiety

Despite hitting three receptors, retatrutide does not activate amylin receptors. That's where cagrilintide comes in. Amylin is a fullness hormone that works in a different part of the brain (the hindbrain) than where GLP-1 signals operate. Think of it this way: GLP-1 tells your gut to slow down, while amylin tells your brain you've had enough — through a separate channel. The stack hypothesis is that layering amylin signaling on top of retatrutide's triple agonism may amplify satiety through these non-overlapping routes.

Complementary Gastric Emptying — Stacked Digestion Slowdown

Both cagrilintide and retatrutide independently slow gastric emptying — meaning food stays in your stomach longer, which extends the feeling of fullness after a meal. When you combine two compounds that both have this effect through different receptor mechanisms, the result may be stronger fullness, but it also raises the risk of nausea, vomiting, constipation, and difficulty tolerating dose increases.

Glucagon + Amylin — Overlapping but Distinct Metabolic Effects

Retatrutide directly activates the glucagon receptor, which pushes the body to burn more energy and oxidize fat. Cagrilintide, through its calcitonin-receptor activity, can also influence glucagon-related signaling — but through a different mechanism. How these two glucagon-adjacent effects interact when combined has not been studied, so the net impact on blood sugar regulation remains unknown.

Cagrilintide + Retatrutide Dosing Protocol & Schedule

This section covers how to dose the cagrilintide + retatrutide stack using a staggered approach — you start one compound first, build tolerance, and then layer in the second. This reduces the risk of overwhelming your digestive system with two potent peptides at once.

Format A: Separate Vials - Staggered Co-Titration

This is the recommended format. Start retatrutide first, then add cagrilintide after GI tolerance is established to reduce compounded nausea and gastric-motility effects.

Format B: Pre-Blended Vial (12.5 mg + 2.5 mg)

Some suppliers list a fixed 5:1 pre-blend (12.5 mg retatrutide + 2.5 mg cagrilintide). This format simplifies handling but prevents independent titration.

Protocol Notes

• Injection logistics: Both compounds are subcutaneous and typically once weekly. Use different injection sites on the same day.
• Oral options: Neither compound is orally bioavailable in these formulations.
• GI management is critical: Slow titration, protein-forward meals, hydration, and lower-fat meals during escalation are commonly used mitigation strategies.
• Do not combine with semaglutide or tirzepatide: Retatrutide already carries GLP-1 activity (plus GIP and glucagon), so overlap increases redundancy and tolerability burden.
• Dysesthesia monitoring (unusual skin sensations): Retatrutide dose escalation has been associated with tingling, numbness, or prickling sensations in clinical programs. If you notice these, note the timing relative to dose increases.

Cagrilintide + Retatrutide Reconstitution Guide

Format A: Separate Vials

The table below shows how much bacteriostatic (BAC) water to add to each vial, what concentration you'll get, and — most importantly — how much liquid to draw into your syringe for each common dose. The "Volume / Units" column gives you the answer in two formats: milliliters (mL) and syringe units, which are the markings on a standard U-100 insulin syringe (where 0.10 mL = 10 units).

Math verification (Retatrutide 10 mg vial, 1.0 mL BAC): concentration = 10,000 mcg/mL. 8 mg dose = 0.80 mL (80 units). 12 mg dose = 1.20 mL (120 units).

Math verification (Cagrilintide 5 mg vial, 2.0 mL BAC): concentration = 2,500 mcg/mL. 2.4 mg dose = 0.96 mL (96 units).

7-Step Reconstitution Instructions

1. Allow vial(s) to reach room temperature for 10-15 minutes.
2. Swab stoppers with alcohol and let them dry.
3. Draw BAC water volume according to target table.
4. Inject BAC water slowly down vial wall (especially important for cagrilintide).
5. Gently swirl/roll to dissolve; do not shake.
6. Confirm solution clarity; discard cloudy or particulate solutions.
7. Label compound, concentration, and date; refrigerate immediately at 2-8 C and use within 28-30 days.

Cagrilintide + Retatrutide Side Effects & Safety

This combination has not been tested directly in a clinical trial. Safety expectations are based on what each compound does on its own. The primary concern is stacked gastrointestinal (GI) side effects — nausea, vomiting, diarrhea, and constipation — because both compounds independently slow digestion through different pathways, and combining them may intensify these effects.

• Amplified GI effects: Both compounds independently carry high rates of nausea, vomiting, diarrhea, and constipation, with highest burden during weeks 9-24 when both are escalating.
• Dysesthesia — unusual skin sensations (retatrutide-specific): Tingling, numbness, or prickling sensations have been reported in retatrutide trials and appear to increase at higher doses.
• Injection-site reactions: More commonly associated with cagrilintide; rotate sites consistently.
• Gallbladder events: Rapid weight loss can increase gallstone risk.
• Multi-source quality risk: Both compounds are investigational; sourcing quality variability is a major safety variable.
• Unknown interaction profile: Combined glucagon-pathway effects are theoretical and not clinically characterized.

For combined side effect considerations when stacking, see the PepPal Side Effects Guide.

Clinical Evidence Context

The table below summarizes the weight-loss evidence for each compound on its own. Percentages refer to average body weight lost from baseline over the study period.

In plain terms, this stack tries to hit weight loss from four directions: reducing appetite (GLP-1), improving how your body processes energy (GIP), increasing calorie burn (glucagon), and amplifying the feeling of fullness after meals (amylin). It covers more biological pathways than any other current peptide stack — but the combination itself has no clinical evidence behind it.

Storage & Handling

Limiting factor: both compounds share similar refrigerated windows, but cagrilintide handling sensitivity (do not shake, discard cloudy solution) is typically the stricter operational constraint.

Cagrilintide + Retatrutide vs. CagriSema vs. Retatrutide Alone

The table below compares this stack against the two most common alternatives: CagriSema (which has actual clinical trial data as a combination) and retatrutide on its own (the simplest option). Look at the "receptor coverage" row to see how many biological pathways each option targets, and the "combination clinical data" row to see how much real-world evidence backs each approach.

Receptor abbreviation key: AMY1-3R = amylin receptors (fullness signaling), CTR = calcitonin receptor (related to amylin), GLP-1R = appetite suppression, GIPR = metabolic efficiency, GCGR = glucagon receptor (energy expenditure and fat burning).

Decision Guidance

• Choose Cagrilintide + Retatrutide only when prioritizing maximum theoretical receptor coverage and accepting highest complexity, cost, and uncertainty.
• Choose CagriSema when prioritizing combination evidence strength and more characterized safety data.
• Choose retatrutide alone when prioritizing strongest single-agent efficacy and simplest protocol logistics.

Related Stacking Protocols

CagriSema (Cagrilintide + Semaglutide)

The parent amylin + GLP-1 model with Phase 3 data and a late-2026 NDA decision timeline. View CagriSema stack.

Cagrilintide + Tirzepatide Stack

A middle-ground model between CagriSema and Cagrilintide + Retatrutide, pairing amylin signaling with dual incretin agonism while excluding glucagon agonism. View Cagrilintide + Tirzepatide stack.

Retatrutide + MOTS-c Stack

A mitochondrial-focused alternative that keeps retatrutide's triple agonism but swaps amylin satiety support for MOTS-c's AMPK and mitochondrial signaling. View Retatrutide + MOTS-c stack.

Higher-Dose CagriSema (2.4/7.2 mg)

Novo Nordisk has also explored higher-dose semaglutide layering with cagrilintide as an alternate pharmaceutical escalation pathway.

Frequently Asked Questions - Cagrilintide + Retatrutide Stack

Sources & Research

1. Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." New England Journal of Medicine, 2023 Link.
2. Eli Lilly "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press Release, 2025 Link.
3. Garvey WT, et al. "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2025 Link.
4. Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." The Lancet, 2021 Link.
5. Enebo LB, Berthelsen KK, Kankam M, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg." The Lancet, 2021 Link.
6. Kruse T, Dahl K, Schaffer L, et al. "Development of Cagrilintide, a Long-Acting Amylin Analogue." Journal of Medicinal Chemistry, 2021 Link.
7. Giblin K, Kaplan LM, Somers VK, et al. "Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials." Diabetes, Obesity and Metabolism, 2026 Link.
8. Fletcher MM, et al. "Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors." Nature Communications, 2025 Link.
9. Dutta D, et al. "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." Indian Journal of Endocrinology and Metabolism, 2024 Link.
10. ClinicalTrials.gov — (NCT05929066), (NCT06131437), (NCT05567796), (NCT05394519).

Related Protocols

Disclaimer